Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) announced its earnings results on Wednesday. The company reported ($1.86) EPS for the quarter, topping the consensus estimate of ($2.06) by $0.20, Zacks reports. The company had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.01 million. Lyell Immunopharma had a negative net margin of 920,285.25% and a negative return on equity of 91.62%.
Lyell Immunopharma Trading Down 4.1%
NASDAQ LYEL traded down $0.64 on Thursday, hitting $14.79. 368,353 shares of the company’s stock were exchanged, compared to its average volume of 138,494. The stock has a 50-day moving average of $10.85 and a 200-day moving average of $16.73. Lyell Immunopharma has a 52 week low of $7.20 and a 52 week high of $45.00. The stock has a market cap of $362.48 million, a price-to-earnings ratio of -1.15 and a beta of -0.04.
Wall Street Analysts Forecast Growth
LYEL has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Thursday, October 15th. Royal Bank Of Canada set a $34.00 target price on Lyell Immunopharma in a research report on Friday, August 14th. Stifel Nicolaus began coverage on Lyell Immunopharma in a report on Thursday, August 6th. They set a “buy” rating and a $36.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $44.00 price target on shares of Lyell Immunopharma in a research report on Tuesday. Finally, Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, October 25th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $40.86.
Get Our Latest Stock Report on Lyell Immunopharma
Lyell Immunopharma News Summary
Here are the key news stories impacting Lyell Immunopharma this week:
- Positive Sentiment: Ronde-cel produced a 91% overall response rate and 77% complete response rate among 44 patients in the pivotal 3L+ trial; in a 37-patient second-line cohort, rates were 95% and 76%. Median progression-free survival was not reached in either group. Lyell also reported no Grade 3 or higher cytokine release syndrome and Grade 3 or higher neurotoxicity in fewer than 10% of patients. The data will be presented at the December ASH meeting. Ronde-cel data announcement
- Positive Sentiment: Lyell agreed to raise about $80 million in a private placement, with proceeds intended to advance ronde-cel toward a planned Biologics License Application submission. The funding may support development and reduce near-term financing pressure. Private placement announcement
- Positive Sentiment: Needham & Company assigned LYEL a “Buy” rating, adding an analyst endorsement amid the clinical update. Needham rating
- Positive Sentiment: Third-quarter adjusted results included a loss of $1.86 per share, narrower than analysts’ expected $2.06 loss. Third-quarter results
- Negative Sentiment: The $80 million placement involves issuing additional common shares, diluting existing investors. Lyell also reported no quarterly revenue and remains loss-making, underscoring its dependence on successful clinical development and future financing. Financing announcement
Lyell Immunopharma Company Profile
Lyell Immunopharma, Inc is a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer. The company aims to improve the durability and effectiveness of T-cell therapies by addressing challenges such as T-cell exhaustion, limited persistence, and inadequate activity within solid tumors.
Lyell’s research and development programs use technologies designed to reprogram and rejuvenate T cells, including approaches involving genetic engineering, epigenetic modification, and chimeric antigen receptor (CAR) T-cell therapy.
Featured Stories
- Five stocks we like better than Lyell Immunopharma
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
- South Korea’s Chip Exports Are Soaring—So Why Is This ETF Down 20%?
Receive News & Ratings for Lyell Immunopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lyell Immunopharma and related companies with MarketBeat.com's FREE daily email newsletter.
